ANEB
Anebulo Pharmaceuticals, Inc.Company with tickers: ANEB
CIK
1815974
CUSIP
034569103
Shares Outstanding
40,784,731
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $4,880,170 | USD | 2025-12-31 | 10-Q | 2026-02-12 |
| Research & Development | $1,974,728 | USD | 2025-12-31 | 10-Q | 2026-02-12 |
| Operating Income | $-4,880,170 | USD | 2025-12-31 | 10-Q | 2026-02-12 |
| Net Income | $-4,157,751 | USD | 2025-12-31 | 10-Q | 2026-02-12 |
| EPS (Basic) | $-0.10 | USD/shares | 2025-12-31 | 10-Q | 2026-02-12 |
| EPS (Diluted) | $-0.10 | USD/shares | 2025-12-31 | 10-Q | 2026-02-12 |